Literature DB >> 35400205

Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis.

Prakash Doddapattar1, Rishabh Dev1, Madankumar Ghatge1, Rakesh B Patel1, Manish Jain1, Nirav Dhanesha1, Steven R Lentz1, Anil K Chauhan1.   

Abstract

BACKGROUND: The glycolytic enzyme PKM2 (pyruvate kinase muscle 2) is upregulated in monocytes/macrophages of patients with atherosclerotic coronary artery disease. However, the role of cell type-specific PKM2 in the setting of atherosclerosis remains to be defined. We determined whether myeloid cell-specific PKM2 regulates efferocytosis and atherosclerosis.
METHODS: We generated myeloid cell-specific PKM2-/- mice on Ldlr (low-density lipoprotein receptor)-deficient background (PKM2mye-KOLdlr-/-). Controls were littermate PKM2WTLdlr-/- mice. Susceptibility to atherosclerosis was evaluated in whole aortae and cross sections of the aortic sinus in male and female mice fed a high-fat Western diet for 14 weeks, starting at 8 weeks.
RESULTS: PKM2 was upregulated in macrophages of Ldlr-/- mice fed a high-fat Western diet compared with chow diet. Myeloid cell-specific deletion of PKM2 led to a significant reduction in lesions in the whole aorta and aortic sinus despite high cholesterol and triglyceride levels. Furthermore, we found decreased macrophage content in the lesions of myeloid cell-specific PKM2-/- mice associated with decreased MCP-1 (monocyte chemoattractant protein 1) levels in plasma, reduced transmigration of macrophages in response to MCP-1, and impaired glycolytic rate. Macrophages isolated from myeloid-specific PKM2-/- mice fed the Western diet exhibited reduced expression of proinflammatory genes, including MCP-1, IL (interleukin)-1β, and IL-12. Myeloid cell-specific PKM2-/- mice exhibited reduced apoptosis concomitant with enhanced macrophage efferocytosis and upregulation of LRP (LDLR-related protein)-1 in macrophages in vitro and atherosclerotic lesions in vivo. Silencing LRP-1 in PKM2-deficient macrophages restored inflammatory gene expression and reduced efferocytosis. As a therapeutic intervention, inhibiting PKM2 nuclear translocation using a small molecule reduced glycolytic rate, enhanced efferocytosis, and reduced atherosclerosis in Ldlr-/- mice.
CONCLUSIONS: Genetic deletion of PKM2 in myeloid cells or limiting its nuclear translocation reduces atherosclerosis by suppressing inflammation and enhancing efferocytosis.

Entities:  

Keywords:  atherosclerosis; gene expression; inflammation; macrophages; pyruvate kinase

Mesh:

Substances:

Year:  2022        PMID: 35400205      PMCID: PMC9050913          DOI: 10.1161/CIRCRESAHA.121.320704

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  38 in total

1.  Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition.

Authors:  M K Chang; C Bergmark; A Laurila; S Hörkkö; K H Han; P Friedman; E A Dennis; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 2.  Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis.

Authors:  Ira Tabas; Karin E Bornfeldt
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

3.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages.

Authors:  Eva M Palsson-McDermott; Anne M Curtis; Gautam Goel; Mario A R Lauterbach; Frederick J Sheedy; Laura E Gleeson; Mirjam W M van den Bosch; Susan R Quinn; Raquel Domingo-Fernandez; Daniel G W Johnston; Jian-Kang Jiang; Jain-Kang Jiang; William J Israelsen; Joseph Keane; Craig Thomas; Clary Clish; Matthew Vander Heiden; Matthew Vanden Heiden; Ramnik J Xavier; Luke A J O'Neill
Journal:  Cell Metab       Date:  2015-01-06       Impact factor: 27.287

4.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Allosteric regulation of pyruvate kinase M2 isozyme involves a cysteine residue in the intersubunit contact.

Authors:  Y Ikeda; T Noguchi
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation.

Authors:  Patricia G Yancey; John Blakemore; Lei Ding; Daping Fan; Cheryl D Overton; Youmin Zhang; MacRae F Linton; Sergio Fazio
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-11       Impact factor: 8.311

7.  Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse.

Authors:  Cheryl D Overton; Patricia G Yancey; Amy S Major; MacRae F Linton; Sergio Fazio
Journal:  Circ Res       Date:  2007-02-15       Impact factor: 17.367

8.  Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis.

Authors:  Canan Kasikara; Maaike Schilperoort; Brennan Gerlach; Chenyi Xue; Xiaobo Wang; Ze Zheng; George Kuriakose; Bernhard Dorweiler; Hanrui Zhang; Gabrielle Fredman; Danish Saleheen; Muredach P Reilly; Ira Tabas
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

9.  Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors.

Authors:  Eva M Palsson-McDermott; Lydia Dyck; Zbigniew Zasłona; Deepthi Menon; Anne F McGettrick; Kingston H G Mills; Luke A O'Neill
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

10.  Smooth Muscle Cell-Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia.

Authors:  Manish Jain; Nirav Dhanesha; Prakash Doddapattar; Manasa K Nayak; Liang Guo; Anne Cornelissen; Steven R Lentz; Aloke V Finn; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-11       Impact factor: 8.311

View more
  1 in total

Review 1.  Immune Cell Activation in Obesity and Cardiovascular Disease.

Authors:  Jamie N Garcia; Celestine N Wanjalla; Mona Mashayekhi; Alyssa H Hasty
Journal:  Curr Hypertens Rep       Date:  2022-09-22       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.